Outcome of surgery for pancreatic neuroendocrine neoplasms

British Journal of Surgery

Volumn 101, Issue 11, 2014, Pages 1405-1412

  Fischer, L ^a   Bergmann, F ^a   Schimmack, S ^a   Hinz, U ^a   Priess S ^a   Muller Stich B P ^a   Werner, J ^a   Hackert, T ^a   Buchler M W ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; EPIDEMIOLOGY; FEMALE; GERMANY; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; NEUROENDOCRINE TUMORS; PANCREAS RESECTION; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; EPIDEMIOLOGIC METHODS; FEMALE; GERMANY; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; YOUNG ADULT;

EID: 84907953353     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9603     Document Type: Article

References (33)

1. Modlin IM, Champaneria MC, Chan A.K., Kidd M. A three-decade analysis of 3911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroenterol 2007; 102: 1464-1473.
2. Schimmack S, Svejda B, Lawrence B., Kidd M, Modlin IM. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg 2011; 396: 273-298.
3. Hauso O, Gustafsson BI, Kidd M, Waldum H.L., Drozdov I., Chan AK et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008; 113: 2655-2664.
4. Yao JC, Hassan M, Phan A., Dagohoy C, Leary C, Mares JE et al. One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072.
5. Fuchs M, Schepp W. [Importance of endoscopy and endosonography for chronic pancreatitis and benign pancreas tumors.] Radiologe 2008; 48: 721-724, 726-731.
6. Grenacher L, Klauss M. [Computed tomography of pancreatic tumors.] Radiologe 2009; 49: 107-123.
7. Oberg K. Pancreatic endocrine tumors. Semin Oncol 2010; 37: 594-618.
8. O'Toole D., Salazar R, Falconi M., Kaltsas G, Couvelard A, de Herder WW et al. Rare functioning pancreatic endocrine tumors. Neuroendocrinology 2006; 84: 189-195.
9. Vagefi PA, Razo O, Deshpande V., McGrath DJ, Lauwers GY, Thayer SP et al. Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Arch Surg 2007; 142: 347-354.
10. Falconi M, Bartsch DK, Eriksson B, Klöppel G, Lopes J.M., O'Connor JM et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012; 95: 120-134.
11. Klöppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2011; 18(SUPPL. 1): S1-S16.
12. Bosman FT, Carneiro F, Hruban R.H., Theise ND (eds). WHO Classification of Tumours of the Digestive System. IARC Press: Lyon, 2010.
13. Klöppel G, Rindi G, Perren A., Komminoth P, Klimstra DS. The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch 2010; 456: 595-597.
14. Hochwald SN, Zee S, Conlon K.C., Colleoni R., Louie O, Brennan MF et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002; 20: 2633-2642.
15. Salazar R, Wiedenmann B, Rindi G., Ruszniewski P. ENETS 2011 consensus guidelines for the management of patients with digestive neuroendocrine tumors: an update. Neuroendocrinology 2012; 95: 71-73.
16. Schmitt AM, Anlauf M, Rousson V., Schmid S, Kofler A, Riniker F et al. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol 2007; 31: 1677-1682.
17. Rindi G, Falconi M, Klersy C., Albarello L, Boninsegna L, Buchler MW et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 2012; 104: 764-777.
18. Liszka Ł, Pajak J, Mrowiec S, Zielińska-Pajak E, Gołka D, Lampe P. Discrepancies between two alternative staging systems (European Neuroendocrine Tumor Society 2006 and American Joint Committee on Cancer/Union for International Cancer Control 2010) of neuroendocrine neoplasms of the pancreas. A study of 50 cases. Pathol Res Pract 2011; 207: 220-224.
19. Casadei R, Ricci C, Pezzilli R., Campana D, Tomassetti P, Calculli L et al. Value of both WHO and TNM classification systems for patients with pancreatic endocrine tumors: results of a single-center series. World J Surg 2009; 33: 2458-2463.
20. Pape UF, Jann H, Müller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008; 113: 256-265.
21. Bettini R, Partelli S, Boninsegna L., Capelli P, Crippa S, Pederzoli P et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 2011; 150: 75-82.
22. Cherenfant J, Stocker SJ, Gage M.K., Du H., Thurow TA, Odeleye M et al. Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. Surgery 2013; 154: 785-793.
23. Haynes AB, Deshpande V, Ingkakul T., Vagefi PA, Szymonifka J, Thayer SP et al. Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. Arch Surg 2011; 146: 534-548.
24. Lee LC, Grant CS, Salomao D.R., Fletcher JG, Takahashi N, Fidler JL et al. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery 2012; 152: 965-974.
25. Colett D. Modelling Survival Data in Medical Research. Texts in Statistical Science. Chapman & Hall/CRC: Boca Raton, 2003.
26. Yao JC, Shah MH, Ito T, Bohas C.L., Wolin EM, Van Cutsem E et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
27. Raymond E, Dahan L, Raoul J.L., Bang YJ, Borbath I, Lombard-Bohas C et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-513.
28. Auernhammer CJ, Goke B. Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin. Gut 2011; 60: 1009-1021.
29. Fischer L, Mehrabi A, Büchler MW. [Neuroendocrine tumors of the duodenum and pancreas. Surgical strategy.] Chirurg 2011; 82: 583-590.
30. Bettini R, Boninsegna L, Mantovani W., Capelli P, Bassi C, Pederzoli P et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol 2008; 19: 903-908.
31. Fischer L, Kleeff J, Esposito I., Hinz U, Zimmermann A, Friess H et al. Clinical outcome and long-term survival in consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg 2008; 95: 627-635.
32. Liu E, Marincola P, Oberg K. Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations. Therap Adv Gastroenterol 2013; 6: 412-419.
33. Yao JC, Phan AT, Jehl V, Shah G., Meric-Bernstam F. Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience. Cancer Res 2013; 73: 1449-1453.